news
NLSDays 2023 (Nordic Life Science Days)
We are pleased to announce that the ERBC group,...
Festival of Biologics 2023
Come and meet us at FOB 23 from 10 to 12...
Follicular lymphoma AVI-PDX models to predict the response to RCHOP
Follicular lymphoma AVI-PDX models to predict...
An in vivo avian model of human melanoma
We are delighted to share the publication of our preclinical Melanoma AVI-PDXTM model.
Our study was conducted with the Hospices Civils de Lyon, the Cancer Research Center of Lyon and the MeLis laboratory of Lyon.
ERBC (European Research Biology Center) Group extends its preclinical expertise with the acquisition of Oncofactory.
This strategic acquisition expands ERBC Group’s...
AVI-PDX™ for breast cancers
We are delighted to present the publication...
US Patent
We are delighted to announce that the US patent...
INOVO : the Oncofactory’s new project with the Carnot Calym Institute and Astrazeneca
February 2021, Astrazeneca, The Carnot Calym Institute and Inserm
Sponsorship from the Rotary club of Lyon
January 2021, The president of the Rotary Club...
Oncofactory presents a poster at SIOP
Oncofactory presents a poster at The 51st...
Publications
The chicken embryo is a model widely used to study human physiology and diseases.
Find out selected literature highlighting the relevance of the chicken embryo as a
model of human physiology and diseases :
The AVI-PDX: An innovative in vivo platform of miniaturized patient-derived xenografts for preclinical developments and personalized medicine.
Frédéric Berget, Clélia Costechareyre, Loraine Jarrosson, Céline Delloye-Bourgeois, and Valérie Castellani
Journal of Clinical Oncology 2020 38:15_suppl, e15607-e15607
Delloye-Bourgeois C, Bertin L, Thoinet K, Jarrosson L, Kindbeiter K, Buffet T, Tauszig-Delamasure S, Bozon M, Marabelle A, Combaret V, Bergeron C, Derrington E, Castellani V (2017) Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma Cancer Cell.
;32(4):427-443.e8. doi: 10.1016/j.ccell.2017.09.006